PharmaCyte Biotech, Inc.
PMCB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001157075
No open-market purchases or sales by PharmaCyte Biotech, Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $586.2K in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding PharmaCyte Biotech, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 34 | 33 | −1 |
| Shares | 3.39M | 3.53M | +136.0K (+4.0%) |
| Value | $9.93M | $10.2M | +$288.8K (+2.9%) |
New holders (5)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 106,886 | $311.0K | 0.00% |
| Dimensional Fund Advisors LP | 29,303 | $85.3K | 0.00% |
| Group One Trading, L.P. | 14,382 | $41.9K | 0.00% |
| Acadian Asset Management LLC | 9,264 | $26.0K | 0.00% |
| Belvedere Trading LLC | 7,135 | $20.8K | 0.01% |
Sold out (6)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Sabby Management, LLC | 97,978 | $287.1K |
| Davy Global Fund Management Ltd | 40,800 | $119.5K |
| FNY Investment Advisers, LLC | 31,100 | $90.0K |
| Jane Street Group, LLC | 20,705 | $60.7K |
| Charles Schwab Investment Management Inc | 17,219 | $50.3K |
| Clearstead Advisors, LLC | 3 | $9 |